154 related articles for article (PubMed ID: 15770730)
1. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
Ma JH; Patrut E; Schmidt J; Knaebel HP; Büchler MW; Märten A
World J Gastroenterol; 2005 Mar; 11(10):1521-8. PubMed ID: 15770730
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory impact of interferon-alpha in combination with chemoradiation of pancreatic adenocarcinoma (CapRI).
Schmidt J; Patrut EM; Ma J; Jäger D; Knaebel HP; Büchler MW; Märten A
Cancer Immunol Immunother; 2006 Nov; 55(11):1396-405. PubMed ID: 16485127
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
[TBL] [Abstract][Full Text] [Related]
4. [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
Wilkowski R; Thoma M; Heinemann V; Rau HG; Wagner A; Stoffregen C; Dühmke E
Strahlenther Onkol; 2003 Feb; 179(2):78-86. PubMed ID: 12590317
[TBL] [Abstract][Full Text] [Related]
5. A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapRI-2.
Märten A; Schmidt J; Ose J; Harig S; Abel U; Münter MW; Jäger D; Friess H; Mayerle J; Adler G; Seufferlein T; Gress T; Schmid R; Büchler MW
BMC Cancer; 2009 May; 9():160. PubMed ID: 19470159
[TBL] [Abstract][Full Text] [Related]
6. The treatment of locally advanced pancreatic carcinoma--a dual challenge.
Kjaer M
Radiother Oncol; 1997 Nov; 45(2):105-7. PubMed ID: 9423998
[No Abstract] [Full Text] [Related]
7. Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
Schmidt J; Jäger D; Hoffmann K; Büchler MW; Märten A
J Immunother; 2007 Jan; 30(1):108-15. PubMed ID: 17198089
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor effect of interferon-ß with gemcitabine in interferon-α-non-responsive pancreatic cancer cells.
Tomimaru Y; Eguchi H; Wada H; Tomokuni A; Kobayashi S; Marubashi S; Takeda Y; Tanemura M; Umeshita K; Mori M; Doki Y; Nagano H
Int J Oncol; 2011 May; 38(5):1237-43. PubMed ID: 21347515
[TBL] [Abstract][Full Text] [Related]
9. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin.
Azria D; Ychou M; Jacot W; Thezenas S; Lemanski C; Senesse P; Prost P; Delard R; Masson B; Dubois JB
Pancreas; 2002 Nov; 25(4):360-5. PubMed ID: 12409830
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer.
Goetze RG; Buchholz SM; Ou N; Zhang Q; Patil S; Schirmer M; Singh SK; Ellenrieder V; Hessmann E; Lu QB; Neesse A
Cells; 2019 Jun; 8(6):. PubMed ID: 31181844
[No Abstract] [Full Text] [Related]
11. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory effect of cisplatin in combination with irradiation on lung tumor cell growth is due to induction of tumor cell apoptosis.
Fujita M; Fujita T; Kodama T; Tsuchida T; Higashino K
Int J Oncol; 2000 Aug; 17(2):393-7. PubMed ID: 10891552
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
Zhu Y; Tibensky I; Schmidt J; Hackert T; Ryschich E; Jäger D; Büchler MW; Märten A
J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
15. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
Soni KS; Thomas D; Caffrey T; Mehla K; Lei F; O'Connell KA; Sagar S; Lele SM; Hollingsworth MA; Radhakrishnan P; Bronich TK
J Pharmacol Exp Ther; 2019 Sep; 370(3):894-901. PubMed ID: 30683666
[TBL] [Abstract][Full Text] [Related]
16. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.
Wilkowski R; Thoma M; Schauer R; Wagner A; Heinemann V
World J Surg; 2004 Oct; 28(10):1011-8. PubMed ID: 15573257
[TBL] [Abstract][Full Text] [Related]
17. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.
Vitale G; van Eijck CH; van Koetsveld Ing PM; Erdmann JI; Speel EJ; van der Wansem Ing K; Mooij DM; Colao A; Lombardi G; Croze E; Lamberts SW; Hofland LJ
Ann Surg; 2007 Aug; 246(2):259-68. PubMed ID: 17667505
[TBL] [Abstract][Full Text] [Related]
18. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram.
Cong J; Wang Y; Zhang X; Zhang N; Liu L; Soukup K; Michelakos T; Hong T; DeLeo A; Cai L; Sabbatino F; Ferrone S; Lee H; Levina V; Fuchs B; Tanabe K; Lillemoe K; Ferrone C; Wang X
Cancer Lett; 2017 Nov; 409():9-19. PubMed ID: 28864067
[TBL] [Abstract][Full Text] [Related]
19. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
20. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.
Huguet F; Fernet M; Giocanti N; Favaudon V; Larsen AK
Target Oncol; 2016 Jun; 11(3):371-81. PubMed ID: 26668065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
